Ebola

Soligenix has entered a collaboration agreement with University of Hawaii at Manoa (UH Manoa) and Hawaii Biotech (HBI) to develop a heat stable subunit Ebola vaccine.

John A Burns School of Medicine’s (JABSOM), tropical medicine, medical microbiology and pharmacology assistant professor Dr Axel Lehrer will also be a part of the collaboration to develop vaccine.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Dr Lehrer is a co-inventor of the Ebola vaccine with HBI that shown proof-of-concept efficacy with subunit Ebola vaccines in non-human primates.

As per terms of the feasibility agreement, Soligenix will assess its proprietary vaccine thermostabilisation technology ThermoVax to stabilise components of the vaccine. The technology is licenced from the University of Colorado.

"There is a great need for a thermostable Ebola vaccine, particularly in areas of the world where filoviruses are endemic and the power supply uncertain."

The collaboration will produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage and will initially focus on a single protein subunit antigen of the potential virus treatment.

See Also:

Dr Lehrer said: "There is a great need for a thermostable Ebola vaccine, particularly in areas of the world where filoviruses are endemic and the power supply uncertain."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ThermoVax previously demonstrated to enhance thermostability of both ricin (RiVax) and anthrax (VeloThrax) subunit vaccines.

The technology has been designed to eliminate the standard cold chain production, distribution and storage logistics required for most vaccines.

ThermoVax technology uses precise lyophilisation of protein immunogens with conventional aluminum adjuvants in combination with secondary adjuvants for rapid onset of protective immunity with the fewest number of vaccinations.

Image: Electron micrograph of an Ebola virus virion. Photo: courtesy of CDC/Cynthia Goldsmith.